NextCure Stock - long-term oncology model under scrutiny
20.06.2026 - 21:56:22 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 21:52 UTC. Details in the imprint.
NextCure (US65343E1082) is a clinical-stage immuno-oncology company listed on Nasdaq. With no major fresh disclosures from investor relations or wire services this weekend, the focus turns to its long-term business model and how it plans to finance and develop its pipeline.
Background and key data on NextCure stock
Key figures, filings and past releases on NextCure help investors gauge the risk profile of this small-cap oncology name.
How the pipeline is positioned
NextCure describes itself as a clinical-stage biopharmaceutical company developing immunomedicines for patients with cancer and related immune disorders, focusing on novel targets in the tumor microenvironment.
The company’s lead program has been NC318, a monoclonal antibody targeting Siglec-15, alongside other earlier-stage assets such as NC410 aimed at modulating immune pathways.
Cash, runway and small-cap reality
As a pre-revenue biotechnology name, NextCure historically has relied on equity offerings and partnerships to fund research and development, a model that leaves shareholders exposed to dilution when capital markets are soft.
Market data platforms show the company firmly in small-cap territory, with the stock trading around low single-digit dollar levels and with institutional investors holding a notable portion of the shares.
The product behind the stock
NextCure’s business model revolves around discovering and developing antibody-based immuno-oncology therapies such as NC318 and NC410, which are designed to re-activate anti-tumor immune responses by targeting suppressive mechanisms in the tumor microenvironment.
Where the stock trades today
NextCure shares (US65343E1082) last closed on Nasdaq at $2.02 on 06/18/2026, according to recent market data, with after-hours trading quoted at $0.00 on the same day.
Key facts on NextCure stock
- Company: NextCure Inc.
- ISIN: US65343E1082
- WKN: A2PPJ2
- Ticker: NXTC
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 2.02 USD
- Market cap: 7.29 million USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of major headline indices such as the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
